Literature DB >> 35503170

Sphingolipids and Cholesterol.

Xian-Cheng Jiang1, Zhiqiang Li2.   

Abstract

Sphingolipids and cholesterol are two lipid partners on cellular membranes where they form specific microdomains, named lipid rafts, which mediate specific cell functions. Sphingomyelin (SM) is one of the major sphingolipids. SM and free cholesterol are also two key lipids on the monolayer of plasma lipoproteins, including chylomicron, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL), which participate in lipid transport in the circulation. Thus, sphingolipids and cholesterol play a fundamental role in cell membrane structure and blood lipid transport. In this chapter we will discuss the relationship between both lipids, on the cell membrane and in the circulation, as well as the impact of such relationship in the development of metabolic diseases.
© 2022. The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Cell membrane lipids; Cholesterol; Lipids in the circulation; Sphingolipids; Sphingomyelin

Mesh:

Substances:

Year:  2022        PMID: 35503170      PMCID: PMC9251731          DOI: 10.1007/978-981-19-0394-6_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   3.650


  164 in total

1.  Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages.

Authors:  Paul A Mueller; Lin Zhu; Hagai Tavori; Katherine Huynh; Ilaria Giunzioni; John M Stafford; MacRae F Linton; Sergio Fazio
Journal:  Circulation       Date:  2018-10-23       Impact factor: 29.690

2.  Lysenin, a novel sphingomyelin-specific binding protein.

Authors:  A Yamaji; Y Sekizawa; K Emoto; H Sakuraba; K Inoue; H Kobayashi; M Umeda
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

3.  Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice.

Authors:  Mohammad Reza Hojjati; Zhiqiang Li; Hongwen Zhou; Songshan Tang; Chongmin Huan; Everlyn Ooi; Shendi Lu; Xian-Cheng Jiang
Journal:  J Biol Chem       Date:  2004-12-06       Impact factor: 5.157

Review 4.  Sphingomyelinases: enzymology and membrane activity.

Authors:  Félix M Goñi; Alicia Alonso
Journal:  FEBS Lett       Date:  2002-10-30       Impact factor: 4.124

5.  Enhanced insulin sensitivity in mice lacking ganglioside GM3.

Authors:  Tadashi Yamashita; Akira Hashiramoto; Martin Haluzik; Hiroki Mizukami; Shoshannah Beck; Aaron Norton; Mari Kono; Shuichi Tsuji; Jose Luis Daniotti; Norbert Werth; Roger Sandhoff; Konrad Sandhoff; Richard L Proia
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

6.  Phase equilibria in the phosphatidylcholine-cholesterol system.

Authors:  J H Ipsen; G Karlström; O G Mouritsen; H Wennerström; M J Zuckermann
Journal:  Biochim Biophys Acta       Date:  1987-11-27

7.  Codetermination of Sphingomyelin and Cholesterol in Cellular Plasma Membrane in Sphingomyelin-Depletion-Induced Cholesterol Efflux.

Authors:  Shuohan Huang; Kang Liu; Dechen Jiang; Danjun Fang
Journal:  Anal Chem       Date:  2018-12-21       Impact factor: 6.986

8.  Effect of the surface lipid composition of reconstituted LPA-I on apolipoprotein A-I structure and lecithin: cholesterol acyltransferase activity.

Authors:  D L Sparks; P G Frank; T A Neville
Journal:  Biochim Biophys Acta       Date:  1998-02-16

9.  Major plasma lipids and fatty acids in four HDL mammals.

Authors:  Eduardo N Maldonado; Emma B Casanave; Marta I Aveldaño
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2002-06       Impact factor: 2.320

10.  Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins.

Authors:  S L Schissel; J Tweedie-Hardman; J H Rapp; G Graham; K J Williams; I Tabas
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.